Back to Search
Start Over
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
- Source :
- Translational Oncology, Translational Oncology, Elsevier, 2021, 14 (2), pp.100984. ⟨10.1016/j.tranon.2020.100984⟩, Translational Oncology, Elsevier, 2021, 14 (2), ⟨10.1016/j.tranon.2020.100984⟩, Translational Oncology, Vol 14, Iss 2, Pp 100984-(2021)
- Publication Year :
- 2021
- Publisher :
- HAL CCSD, 2021.
-
Abstract
- Highlights • Angiogenesis is critical to the development and survival of solid tumors. • Vanucizumab inhibits both vascular endothelial growth factor and angiopoietin-2. • Vanucizumab exhibits anti-tumor, anti-angiogenic and anti-metastatic effects. • It markedly reduced blood-vessel markers in tumor/skin samples in cancer patients. • Skin biopsies are a valuable surrogate for studying angiogenesis-related mechanisms.<br />Vanucizumab is a novel bispecific antibody inhibiting vascular endothelial growth factor (VEGF-A) and angiopoietin-2 (Ang-2) that demonstrated safety and anti-tumor activity in part I of a phase I study of 42 patients with advanced solid tumors. Part II evaluated the pharmacodynamic effects of vanucizumab 30 or 15 mg/kg every 2 weeks in 32 patients. Serial plasma samples, paired tumor, and skin-wound-healing biopsies were taken over 29 days to evaluate angiogenic markers. Vanucizumab was associated with marked post-infusion reductions in circulating unbound VEGF-A and Ang-2. By day 29, tumor samples revealed mean reductions in density of microvessels (−32.2%), proliferating vessels (−47.9%) and Ang-2 positive vessels (−62.5%). Skin biopsies showed a mean reduction in density of microvessels (−49.0%) and proliferating vessels (−25.7%). Gene expression profiling of tumor samples implied recruitment and potential activation of lymphocytes. Biopsies were safely conducted. Vanucizumab demonstrated a consistent biological effect on vascular-related biomarkers, confirming proof of concept. Skin-wound-healing biopsies were a valuable surrogate for studying angiogenesis-related mechanisms.
- Subjects :
- 0301 basic medicine
Cancer Research
Pathology
medicine.medical_specialty
Vanucizumab
Skin wound
[SDV]Life Sciences [q-bio]
CD, cluster of differentiation
Phases of clinical research
[SDV.CAN]Life Sciences [q-bio]/Cancer
CNS, central nervous system
FFPET, formalin-fixed paraffin-embedded tissues
lcsh:RC254-282
miRNA, micro RNA
Angiopoietin-2
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Medicine
IF, immunofluorescence
Mode of action
IQR, interquartile range
Original Research
integumentary system
business.industry
MVD, microvessel density
Micro vessel density
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
VEGF, vascular endothelial growth factor
ANG, angiopoietin
3. Good health
Phase i study
Gene expression profiling
Vascular endothelial growth factor
030104 developmental biology
Oncology
chemistry
030220 oncology & carcinogenesis
Pharmacodynamics
VGS, vanucizumab gene signature
Phase I clinical trial
[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology
business
IHC, immunohistochemistry
Biomarkers
Subjects
Details
- Language :
- English
- ISSN :
- 19447124 and 19365233
- Database :
- OpenAIRE
- Journal :
- Translational Oncology, Translational Oncology, Elsevier, 2021, 14 (2), pp.100984. ⟨10.1016/j.tranon.2020.100984⟩, Translational Oncology, Elsevier, 2021, 14 (2), ⟨10.1016/j.tranon.2020.100984⟩, Translational Oncology, Vol 14, Iss 2, Pp 100984-(2021)
- Accession number :
- edsair.doi.dedup.....4ede3c26551da25bb87f68efc11ddf03